buprenorphin/naloxon "g.l. pharma" 8+2 mg resoribletter, sublinguale
g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 8+2 mg
buprenorphin/naloxon "g.l. pharma" 2+0,5 mg resoribletter, sublinguale
g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 2+0,5 mg
buprenorphin/naloxon "mylan" 8+2 mg resoribletter, sublinguale
mylan ab - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 8+2 mg
buprenorphin/naloxon "mylan" 2+0,5 mg resoribletter, sublinguale
mylan ab - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 2+0,5 mg
buprenorphin/naloxon "g.l. pharma" 4+1 mg resoribletter, sublinguale
g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 4+1 mg
suboxone
indivior europe limited - buprenorphin, naloxon - opioid-relaterede lidelser - andre narkotika stoffer - substitutionsbehandling for opioidmisbrug, inden for rammerne af medicinsk, social og psykologisk behandling. intentionen med naloxon-komponenten er at afskrække intravenøs misbrug. behandlingen er beregnet til brug hos voksne og unge over 15 år, som har accepteret at blive behandlet for afhængighed.
buprenorphine "orifarm" 8 mg resoribletter, sublinguale
orifarm generics a/s - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg
buprenorphine "orifarm" 2 mg resoribletter, sublinguale
orifarm generics a/s - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg
buprenorphine "teva" 2 mg resoribletter, sublinguale
teva b.v. - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg
buprenorphine "teva" 8 mg resoribletter, sublinguale
teva b.v. - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg